Načítá se...

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

Rapid development of the small molecule proteasome inhibitor bortezomib has yielded important clinical benefit for patients with multiple myeloma. Early phase clinical trials suggest the agent has similar efficacy in Waldenströms Macroglobulinemia. Optimization of bortezomib-based therapy, though, r...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: LAUBACH, JACOB P., MITSIADES, CONSTANTINE S., ROCCARO, ALDO M., GHOBRIAL, IRENE M., ANDERSON, KENNETH C., RICHARDSON, PAUL G.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3133638/
https://ncbi.nlm.nih.gov/pubmed/19452315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190902866732
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!